Seven patients die: MacroGenics closes its B7-H3-targeted solid tumor clinical trial
- Subversive discovery: Can lymph nodes promote the success of cancer immunotherapy?
- Major Discovery: Cancer cell PD-L1 does not inhibit T cell toxicity
- The new coronavirus may kill cancer cells and achieve a permanent cure!
- Why did the Alzheimer’s drug candidate BACE1 inhibitor fail?
- LRTI Death: Research spanning 80 years confirms for the first time
- The decline of the global antibiotic market is threatening the development of new drugs
Seven patients die: MacroGenics closes its B7-H3-targeted solid tumor clinical trial
- More than 1 million Chinese died after China quit “Zero-COVID policy”?
- Why is Vinyl chloride listed as a Class A “known human carcinogen” ?
- First human trial of HIV gene therapy: A one-time cure will be achieved if successful!
- New breakthrough in CAR-T cell therapy: Lupus erythematosus patients achieved treatment-free remission for up to 17 months
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
Seven patients die: MacroGenics closes its B7-H3-targeted solid tumor clinical trial.
Recently, the B7-H3- targeted monoclonal antibody developed by MacroGenics , Enoblituzumab, in the treatment of head and neck squamous cell carcinoma in the phase 2 clinical trial, 7 patients died, MacroGenics announced the closure of this clinical trial.
This is also the second setback for MacroGenics in its three R&D pipelines for the B7-H3 target. In 2020, the company stopped the development of its B7-H3×CD3 bispecific antibody .
This time, the development of the B7-H3 monoclonal antibody was stopped . The clinical trial of B7-H3 ADC is still advancing and is in Phase 2 clinical phase.
In this phase 2 clinical trial of Enoblituzumab combined with PD-1 mAb in the treatment of head and neck squamous cell carcinoma, 7 of 62 patients participating in the clinical trial died (related mortality reached 11.3%) , these patients died May be related to bleeding events.
Bleeding is a known risk for head and neck squamous cell carcinoma, but the incidence of this risk should be lower than in this phase 2 clinical trial.
MacroGenics Chief Executive Officer Scott Koenig said in a statement that he was surprised by the multiple deaths in the clinical trial, as previous early-stage clinical trials had not seen such events.
In a phase 3 clinical trial of Bevacizumab developed by Roche in the treatment of head and neck squamous cell carcinoma, the bleeding-related mortality rate of patients in the treatment group was 3.6%, while the blood-related mortality rate of patients in the previous clinical trial of MacroGenics was less than 1 %.
The data prompted MacroGenics to halt the clinical trial, although it cannot yet prove that the patient’s death was related to the treatment.
In addition to the monoclonal antibody Enoblituzumab, MacroGenics has five R&D pipelines, including two ADC drugs ( B7-H3 target and ADAM9 target respectively ) , and three bispecific antibodies (PD-1 × CTLA- 4. PD-1×LAG-3, CD123×CD3) .
References :
https://macrogenics.com/pipeline/
Seven patients die: MacroGenics closes its B7-H3-targeted solid tumor clinical trial
(source:internet, reference only)
Disclaimer of medicaltrend.org
